Protection hepatitis vaccine Yupik Eskimo population Seven-year results long-term immunogenicity protection plasma-derived hepatitis vaccine Heptavax cohort susceptible persons study susceptible persons three-dose regimen hepatitis vaccine years vaccinees antibody surface antigen anti-HBs levels mIU/mL Anti-HBs levels years age level anti-HBs year first dose years first dose vaccine vaccine responders persons antibody core antigen level anti-HBs None detectable hepatitis surface antigen clinical hepatitis update ongoing study risk hepatitis virus infection persons initial anti-HBs response virus vaccine mIU/mL low initial antibody level 